Features

The return of chloroquine

Clinical Practice
The resurgence in the prescribing of the potentially maculotoxic drug hydroxychloroquine has led the Royal College of Ophthalmologists to produce a new screening guideline of which, Bill Harvey argues, we should be aware

Chloroquine is a drug that was widely used both to prevent and to treat the effects of malaria and, despite the development of resistant malarial strains, is still used in this form. Like other anti-malarial drugs, chloroquine and its metabolite sister drug hydroxychloroquine have a number of well-known ocular side effects, some sight-threatening. As resistance to the drugs increased and the impact of malaria in northern Europe subsided, these effects were seen less and less. However, in recent decades, the drugs have found a new lease of life in the management of a number of inflammatory diseases and so an understanding of the ocular consequences is again back on the radar.

Register now to continue reading

Thank you for visiting Optician Online. Register now to access up to 10 news and opinion articles a month.

Register

Already have an account? Sign in here